Indeed, by taking advantage of VDR and Eag1 increased expression in a high number of breast cancer tumors [4], [15], [24], this therapeutic approach could be validated in future preclinical studies and clinical trials of mammary carcinoma or any other malignant neoplasm over-expressing Eag1 and VDR. This evidence concerns the gene KCNH1 and breast carcinoma.